Loading
Life sciences · Journal article
Immunological Investigations · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background β-elemene (ELE), a natural sesquiterpene with antitumor properties, exerts immunomodulatory effects on osteosarcoma (OS), but its impact on the tumor microenvironment and cancer stemness remains unclear. This study investigated how ELE reprograms tumor-associated macrophages (TAMs) to suppress OS progression.Methods We combined single-cell RNA sequencing (scRNA-seq) of a murine OS model with functional validations, including macrophage polarization assays, co-culture systems, western blot, RT-PCR, ELISA, tumorsphere formation, and rescue experiments (CCL2 overexpression, Akt activation).Results ELE treatment significantly inhibited OS tumor growth and promoted apoptosis. scRNA-seq revealed that ELE skewed TAMs from immunosuppressive M2 to antitumor M1 phenotypes, concurrently reducing the osteosarcoma stem-like cell (OSC) population. Cell communication analysis showed enhanced M1-OSC pro-inflammatory signaling (e.g. TNF, IL-1) and suppressed M2-derived CCL2 signaling. Mechanistically, ELE downregulated CCL2 secretion from M2 macrophages, inhibiting Akt phosphorylation and subsequent β-catenin activation, which led to reduced expression of stemness markers (SOX2, NANOG, CD133) and impaired OSC self-renewal and invasion. These effects were reversed by CCL2 overexpression or Akt activation.Conclusion ELE attenuates OS stemness by polarizing TAMs toward an M1 phenotype and disrupting the CCL2/Akt/β-catenin axis, revealing a novel immunometabolic mechanism for OS therapy.